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EPIDEMIOLOGY AND PREVENTION
Couple-Based HIV Prevention for Low-IncomeDrugUsers
From New York City: A Randomized Controlled Trial to
Reduce Dual Risks
Nabila El-Bassel, DSW,* Louisa Gilbert, PhD,* Elwin Wu, PhD,* Susan S. Witte, PhD,*
Mingway Chang, PhD,* Jennifer Hill, PhD,† and Robert H. Remien, PhD‡
Objective: Dual threats of injection drug use and risky sexual
practices continue to increase transmission of HIV and other sexually
transmitted Infections (STIs) among drug-using couples in low-income
communities in the United States. Two hypotheses were tested: (1)
‘‘intervention effect’’—whether the HIV risk-reduction intervention
provided to the couple or individual partners would be more efficacious
in decreasing number of unprotected sexual acts and having a lower
cumulative incidence of biologically confirmed STIs over the 12-month
follow-up period compared with the attention control condition; and
(2) ‘‘modality effect’’—whether the HIV risk-reduction intervention
would be more likely to decrease the number of unprotected sexual acts
and have a lower cumulative STI incidence when delivered to a couple
compared with the same intervention delivered to an individual.
Design: Using a randomized controlled trial, 282 HIV-negative
drug-using couples (564 individuals) were randomly assigned to
receive either of the following: (1) couple-based risk reduction; (2)
individual-based HIV risk reduction, or (3) couple-based wellness
promotion, which served as an attention control condition.
Results: Over 12-month follow-up, there was a 30% reduction in
the incidence rate of unprotected acts of intercourse with the study
partners compared with participants in the attention control arm.
Moreover, over 12-month follow-up there was a 29% reduction in the
same outcome in the couple arm compared with the individual arm
with a 41% reduction at the 12-month follow-up.
Conclusion: A couple-based approach that addresses drug and
sexual risks and targets low-income active drug users may help curb
the HIV epidemic.
KeyWords: couple-based intervention, drug-using couples, injection
drug use, risky sexual practice, sexually transmitted infections
(J Acquir Immune Defic Syndr 2011;58:198–206)
INTRODUCTION
Dual threats of injection drug use and risky sexual
practices continue to fuel transmission of HIV and other
sexually transmitted infections (STIs) in low-income urban
communities with concentrated HIV epidemics.1 Thirty years
of research have found that injection and noninjection drug use
are associated with having unprotected sex, having concurrent
sexual partners, and contracting HIV and other STIs among
heterosexuals in committed relationships.2–4 Research also
suggests that sharing syringes is prevalent among heterosexual
injection drug-using couples.5 Among heterosexuals, sexual
transmission of HIV and other STIs most frequently occurs in
the context of intimate relationships.6 HIV-negative couples in
established relationships report low rates of condom use even
when they engage in drug-related or sexual HIV risks with
outside partners.7 These epidemiological trends underscore the
need for HIV prevention approaches that synergistically focus
on reducing both drug-related and sexual HIV risk behaviors
among HIV-negative drug-involved heterosexual couples.
Research over the past decade suggests the efficacy of
a dyadic-focus as the unit of change in reducing sexual HIV risk
behaviors among heterosexual couples and decreasing unsafe
injection behaviors among heterosexual drug-involved couples.8–13
This research suggests that couple-based approaches provide an
opportunity for both partners to improve their HIV/STI
knowledge, disclose and identify sensitive HIV risks, and to
develop mutual goals and joint responsibility for protecting each
other from HIV/STIs.9,14,15 Despite evidence suggesting the
potential efficacy of couple-based HIV prevention approaches,
only 4 intervention studies with heterosexual couples have been
conducted in the United States.9,15–17 These couple-based studies
have exclusively focused on sexual risk reduction, targeting mainly
HIV serodiscordant and HIV-positive concordant couples. To date,
none have focused exclusively on drug-using couples or
specifically addressed injection-related risks or drug-related
triggers for unsafe sex.18
We report on a randomized controlled trial (RCT)
designed to address these gaps in couple-based HIV pre-
vention research by focusing exclusively on HIV-negative
concordant couples where one or both use drugs. Building on
prior couple-based HIV research that resulted in an evidence-
based HIV prevention model for couples (connect), in-
tervention components were modified to address dyadic drug
risk reduction and drug-related unsafe sex.15 This culminated
in a couple-based HIV risk-reduction intervention (connect 2)
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specifically for drug-involved HIV-negative concordant het-
erosexual couples. For this RCT, couples were recruited
primarily through street outreach and randomly assigned to
receive 1 of 3 interventions as follows: (1) a couple-based HIV
risk reduction; (2) an individual-based HIV risk reduction that
delivered the same content as the couple-based condition but
was provided to either the male or female drug-using partner
alone; or (3) a couple-based wellness promotion that served as
an attention control condition. This RCT tested 2 primary
hypotheses as follows: (1) ‘‘intervention effect’’—whether the
HIV risk-reduction intervention provided to the couple or an
individual partner would be more efficacious in decreasing the
number of unprotected acts of intercourse and having a lower
cumulative incidence of biologically confirmed STIs over the
12-month follow-up period compared with the attention
control condition; and (2) ‘‘modality effect’’—whether the
HIV risk-reduction intervention would be more likely to
decrease the number of unprotected acts of intercourse and
have a lower cumulative STI incidence when delivered to
a couple compared with the HIV risk-reduction intervention
delivered to an individual.
METHODS
Study Design and Population
The Institutional Review Board of Columbia University
approved this RCT study, which was conducted between
November 2005 and September 2010 in New York City.
Participants were recruited through street outreach, homeless
shelters, soup kitchens, syringe exchange programs, and word-
of-mouth. Most qualified couples came through street
outreach. Before screening, potential participants were asked
if they would like to complete a brief interview to see if they
would be eligible to participate in a study where they would
learn ways to protect themselves and their partner from getting
HIV and other STIs. If they expressed interest, consent was
obtained by recruiters followed by a screening interview that
covered sociodemographics and eligibility criteria. Individuals
who met initial eligibility criteria were asked to invite their
main sexual partner to participate. A letter to their partner
introducing the study was given to potential participants.
Partners interested in participating were screened. If eligible,
the recruiter obtained written informed consent from the
partners before enrollment and scheduled the couple for
baseline data collection. Participants received monetary
compensation for completing the baseline assessment and
each follow-up assessment.
Couples were eligible to participate if (1) both were
18 or older and at least 1 partner was 18–40; (2) both tested
HIV negative using OraQuick and OraSure assays; (3) both
identified each other as their main, regular partner, boy/girl-
friend, spouse, lover; (4) both reported that they have been
together for at least 6 months and couple status was verified by
separately asking each partner standard questions about their
relationship (eg, when and where did you first meet your
partner?); (5) both intended to remain together for at least one
year; (6) at least 1 partner reported using illicit drugs in the
prior 90 days and was seeking or in drug treatment; (7) at least
1 partner reported having had unprotected intercourse with the
other in the prior 90 days. Additionally, at least 1 partner had to
report 1 or more of the following HIV risk criteria: (1) sex with
other partners in the prior 90 days; (2) injecting drugs in the
prior 90 days; or (3) self-reported being diagnosed with an STI
in the prior 90 days. Couples were excluded from the study if
either partner (1) reported experiencing severe intimate partner
violence in the past year by the other partner, as assessed by
subscales of the Revised Conflict Tactics Scale19; (2) exhibited
a severe cognitive or psychiatric impairment assessed during
informed consent; (3) did not sufficiently understand English;
(4) reported intentions to conceive a baby in the next year; or
(5) reported an intent to relocate in the coming year. Although
only 1 partner needed to report having had unprotected anal or
vaginal sex with their study partner, in 94% of the enrolled
couples, both partners reported having had at least 1 episode.
Randomization
Couples were randomized to the couple risk reduction,
individual risk reduction, or the couple wellness promotion
conditions at the time of their arrival at their first session
(within 10 days from baseline, allowing sufficient time to
receive HIV and STI test results) (Fig. 1). The gender of the
index participant (the one who reported drug use) was used as
a blocking factor to balance the proportion of couples with
drug-involved female and male participants across study arms.
If both partners met drug involvement eligibility criteria, one
partner was designated randomly as the index participant.
Procedures
All 3 intervention conditions consisted of 7 structured
2-hour sessions delivered weekly by a single female or male
facilitator—matched to the gender of the index participant—
who had at least a bachelor’s degree and 2 years of HIV
prevention experience. Quality assurance (QA) procedures
were implemented by digitally recording all intervention
sessions. Recordings and session-specific QA checklists were
reviewed to monitor fidelity of implementation of all 3 con-
ditions and to provide corrective feedback to facilitators.
The couple-based HIV risk-reduction intervention was
guided by social cognitive theory and a relationship-oriented
ecological framework.20,21 The core components of this
intervention focus on both sexual and drug risk reduction
(1) encouraging both partners to disclose and identify mutual
drug-related and sexual risks; (2) modeling, role-playing and
practicing couple communication, negotiation and problem
solving skills that both partners may employ together to reduce
their drug-related and sexual risks; (3) practicing technical
condom use placement skills along with a broader repertoire of
pleasurable safer sex activities and syringe disinfection skills;
and (4) enhancing the couple’s motivation to protect each other
and set mutual risk-reduction goals. Facilitators were trained to
validate the relationship’s strengths of commitment, love, trust,
and empower the dyad to enact protective behaviors. A safe
environment was created where sensitive or taboo topics
(eg, outside sexual partners) related to a couple’s risks could be
disclosed and addressed.
The individual risk-reduction intervention covered the
same content, skills, and sequencing of activities as the couple
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risk reduction but was delivered to either the male or female
drug-involved partner in individual sessions by a facilitator of
the same gender. In these individual sessions, facilitators were
trained to model and role play communication, negotiation,
and problem-solving skills with participants and encouraged
them to practice these HIV-related skills and share HIV
information with their partners in homework activities.
The couple wellness promotion comparison interven-
tion was designed to control for nonspecific effects (eg,
Hawthorne effect, couple interaction). Also guided by social
cognitive theory, the core components of the intervention
consist of 7 weekly 2-hour sessions and employed the same
structure as the HIV risk-reduction sessions. The couple
wellness promotion comparison intervention focuses on
maintaining a healthy diet, promoting physical fitness in
daily routines, promoting age-appropriate recommendations
for screening for common diseases such as cancers, heart dis-
ease, diabetes, etc., improving access to health care services
by identifying and addressing service barriers, and learning
stress-reduction exercises.
The participants in all 3 conditions provided behavioral
and biological outcome data at baseline, immediate post-
intervention, and at 6-month and 12-month postintervention
time points. An audio computer–assisted self-interview
(ACASI) was used to collect self-reported data on drug-
related and sexual behavioral outcomes and sociodemographic
variables. ACASI provided both audio and video presentation
of the questions and response options on a computer enabling
participants with low literacy to respond to questions. ACASI
was used to collect the participant’s self-reported data on
sexual behaviors with their study partner and with all other
partners in the prior 90 days, including number of vaginal and
anal intercourse acts, number of unprotected vaginal or anal
intercourse acts with their study partners and with all other
partners, consistent condom use (eg, used a condom 100% of
time during vaginal sex), and incidence of concurrent sexual
partners in the past 90 days at baseline and all follow-ups. The
timeline follow-back method was used to enhance recall of
sexual behaviors. The primary behavioral outcome was the
number of unprotected acts of vaginal intercourse. The reports
FIGURE 1. CONSORT flow diagram
of project connect two.
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of conjoint sexual behaviors between couple partners were
correlated at a high level of significance (P , 0.001 for all
conjoint sexual behavioral measures). Discrepant reports
between 2 partners on conjoint behaviors were handled and
treated in the error terms modeling individual’s responses
based on their couple unit in the multilevel mixed-effect
models.
Drug risk behavioral outcomes included whether or not
and number of times injection drugs were used in the past 90
days and number or times syringes, cookers, cotton, or rinse
water were shared with another user in the past 90 days. In
addition, self-reported data on frequency and type of drug use
in the past 90 days were collected for the following substances:
cocaine, crack, heroin, cannabis, and unprescribed sedatives,
opiates, and stimulants.
To complement self-reports of primary behavioral
outcomes, we assessed biologically confirmed STI cumulative
incidence over the 12-month follow-up period. All participants
were asked to provide a self-collected urine specimen after
completing the ACASI. Molecular assays of urine specimens
were performed for Chlamydia trachomatis and Neisseria
gonorrhea using BD ProbeTect. Urine specimens were tested
for Trichomonas vaginalis using nucleic acid amplification.22
Participants with positive STI test results were referred for
single-dose antimicrobial treatment and risk-reduction coun-
seling per Centers for Disease Control and Prevention
recommendations. If either partner tested positive for an
STI, both were recommended for treatment. If participants
tested positive for any STI at any assessment visit, they were
considered an incident STI case for that visit. HIV testing was
repeated at the 12-month follow-up assessment using
OraQuick and OraSure assays.
Statistical Analysis
Consistent with an intent-to-treat approach, participants
were analyzed based on their experimental assignment in
estimating intervention effects. To detect a reduction in the
primary outcome (number of unprotected vaginal sex acts with
a study partner) with effect sizes at least as small as those
observed with our prior couple-based and assuming a = 5%
(2 sided) and 1-b = 80%, a sample size of 90–95 couples per
arm was necessary given an anticipated dropout rate of 15%–
20%. To handle nonindependence in observations, multilevel
mixed-effects models were employed. Each observation at the
first level of the model represents an individual measurement
at 1 of the 3 posttreatment time points. Random effect
parameters in the model account for dependencies present with
each of 2 types of grouping couple and time point. Multilevel
mixed-effects Poisson regressions were used to estimate
effects of the intervention on the number of unprotected acts of
intercourse; corresponding effect estimates are reported as
incident rate ratios (IRR) and corresponding 95% confidence
intervals (CIs). Multilevel mixed-effects logistic regressions
were used to estimate effects on consistent condom use during
vaginal sex, any unprotected anal sex, having concurrent
partners, injecting drugs, sharing needles or syringes, and
sharing works, cooker, cotton, or rinse water; for these effect
estimates, odds ratios and 95% CIs are reported. All available
data on participants who were randomized were used in the
models. Due to the low prevalence of STI at baseline and low
cumulative incidence over the follow-up period, the bi-
ologically assayed outcomes were not included in these
multilevel analyses.
Orthogonal contrast coding was used to test separately
for intervention effect (couple and individual risk reduction
jointly vs. couple wellness promotion) and modality effect
(couple risk reduction vs. individual risk reduction) within one
model. To test for an intervention effect, the coding for couple
risk reduction, individual risk reduction, and health promotion
were +1/3, +1/3, and 22/3, respectively. To test for modality
effects, the coding for couple risk reduction, individual risk
reduction, and health promotion were+1/2, 21/2 and 0,
respectively. All the multilevel models adjusted for the
baseline measure of the outcome and gender.
Our attrition analysis comparing the sociodemographic
variables of those who completed all 3 follow-up assessments
(completers) versus those who missed 1 or more follow-up
assessments (noncompleters) found no differences between
completers and noncompleters with respect to age, marital
status, income, employment status, whether recently in-
carcerated or in jail, and whether in substance abuse treatment
or use of illicit drugs in the past 30 days. However, completers
were more likely than noncompleters to be African American,
older, and less likely to be homeless. To assess whether these
sociodemographic differences between completers and non-
completers may have influenced the intervention outcomes, we
examined intervention outcomes using covariance adjustment
for baseline outcome, gender, ethnicity, age, and homeless-
ness. Patterns of significance did not change and point
estimates for intervention/modality effects changed less than
1%. Because the point estimates and significance did not
change, we presented the results using models that had as few
covariates as possible following the principle of parsimony.
This study is registered with ClinicalTrials.gov, number
NCT01285349.
RESULTS
Figure 1 presents a CONSORT flow diagram depicting
participant flow: 1616 individuals completed the eligibility
screening interview and 865 were eligible; 346 couples (692
individuals) consented and completed baseline interviews and
HIV/STI testing. Twenty couples were excluded at baseline
because at least 1 partner tested positive for HIV. Of the remaining
326 couples, 282 couples returned for a first session and were
randomized (87% participation rate), thus constituting the study
sample as follows: 95 couples (n = 190 participants) were
randomized to the couple HIV risk-reduction condition; 92
couples (n = 184 participants) were randomized to the individual
HIV risk reduction condition for the index drug-using partner and
95 couples (n = 190 participants) were randomized to the couple
wellness promotion condition. Attendance at intervention
sessions for all 3 conditions was high. Participation rates for
completing all 7 sessions of the intervention were as follows: 72%
for couple risk reduction, 66% for the individual risk reduction,
and 76% for couple wellness promotion. No adverse events were
detected by study staff or by QA procedures. We completed 489
immediate postintervention tests (IPTs) follow-up assessments
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averaging an 87% retention rate, 421 completed their 6 months
assessments (75% retention rate), and 428 individuals completed
their 12 months assessments (76% retention rate). Follow-up rates
did not vary significantly among the 3 conditions.
Table 1 reports baseline sociodemographic and drug
treatment characteristics. The average age of participants was
365 years (SD = 71). The majority identified as black or
Latino. Less than half indicated being married. Three-quarters
were homeless, and most were unemployed and living below
the poverty line. One-fifth (21%) reported recent incarceration.
Table 2 presents baseline sexual behaviors and drug risk
characteristics. The sample reported engaging in a range of
sexual and drug-related risk behaviors, including high
incidence of unprotected sex acts with study partners and
across all partners. About one-third reported having had sex
with other partners during the past 90 days and 16% reported
injecting drugs in the past 30 days. Although only 1 partner
needed to report using drugs in the past 30 days to be eligible,
82% of the participants indicated drug use in the past 30 days.
Almost two-thirds (63%) used crack/cocaine in the past 30
days and 16% injected drugs in the past 30 days. Baseline
characteristics reported in Table 1 did not vary significantly by
intervention condition.
Table 3 presents the descriptive statistics of self-reported
sexual and drug risk outcomes and biological STI outcomes by
time and by condition. Prevalence of the 3 STIs that we tested
for was low at the baseline assessment and was even lower at
each follow-up assessment. There were only 23 cumulative
incident cases of any confirmed new STI over the entire
follow-up period. The 12-month follow-up HIV testing only
detected seroconversion of 1 individual.
Table 4 presents the results from multilevel analysis
examining the effects of intervention (couple and individual
risk reduction jointly vs. couple wellness promotion) and the
effects of modality (couple risk reduction vs. individual risk
reduction) with respect to the sexual risk behavior outcomes
after adjusting for the baseline measures of the outcomes and
gender. The results indicate that, over the entire follow-up
period, there was a 30% reduction in the incidence rate
of unprotected acts of intercourse with their study partners
for the participants in the 2 risk-reduction intervention
conditions compared with the participants in the couple
wellness promotion condition (IRR = 070; 95% CI = 053 to
092) and a 29% reduction when comparing couple risk
reduction with Individual Risk Reduction (IRR = 071; 95%
CI = 051, 097). These intervention effects were significant at
IPT (IRR = 058; 95% CI = 038, 088) and 6-month follow-up
(IRR = 070; 95% CI = 054, 092) but not at 12-month
follow-up (IRR = 085; 95% CI = 055, 132). Although the
modality effect was not significant at IPT (IRR = 084; 95%
CI = 052, 135), participants in the Couple Risk Reduction
condition experienced a 30% reduction of unprotected acts of
intercourse at 6-month follow-up (IRR = 070; 95% CI = 051,
096) and a 41% reduction at 12-month follow-up (IRR = 059;
95% CI = 035 to 099) compared with iIndividual risk
reduction participants.
We also examined effects of the intervention and modality
on injecting drug use in the past 90 days among the total sample.





Reduction (n = 190)
Individual Risk
Reduction (n = 183)
Couple Wellness
Promotion (n = 190)
Age (yrs): mean (SD) 36.5 (7.1) 36.1 (7.4) 36.3 (7.2) 37.0 (6.8)
Year of schooling: mean (SD) 11.6 (2.9) 11.4 (3.2) 11.4 (2.8) 11.8 (2.6)
Ethnicity†
Black 275 (50%) 91 (50%) 88 (49%) 96 (51%)
Latino 150 (28%) 50 (28%) 52 (29%) 48 (26%)
White 62 (11%) 18 (10%) 23 (13%) 21 (11%)
Other 61 (11%) 22 (12%) 16 (9%) 23 (12%)
Marital status
Single 252 (45%) 90 (47%) 84 (46%) 78 (41%)
Married 241 (43%) 72 (38%) 78 (43%) 91 (48%)
Divorced/separated/widowed 70 (12%) 28 (15%) 21 (11%) 21 (11%)
Monthly income
#$400 423 (75%) 135 (71%) 139 (76%) 149 (78%)
$401 to $850 99 (18%) 44 (23%) 26 (14%) 29 (15%)
$$851 41 (7%) 11 (6%) 18 (10%) 12 (6%)
Unemployed 456 (81%) 152 (80%) 152 (83%) 152 (80%)
Homeless 415 (74%) 140 (74%) 138 (75%) 137 (72%)
In jail or incarcerated in the past 90 days‡ 120 (21%) 30 (18%) 42 (23%) 48 (25%)
Attending drug or alcohol
treatment in the past 90 days§
267 (48%) 98 (52%) 84 (46%) 85 (45%)
*The data for one man was lost due to computer failure.
†The valid sample sizes were (couple risk reduction, individual risk reduction, couple wellness promotion) = (181, 179, 188).
‡The valid sample sizes were (couple risk reduction, individual risk reduction, couple wellness promotion) = (190, 181, 190).
§The valid sample sizes were (couple risk reduction, individual risk reduction, couple wellness promotion) = (189, 183, 190).
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Although the effects were not significant for intervention or
modality at the 005 level, most likely due to the relatively low
prevalence of injection drug use (16%, n = 91), a promising
effect for injection drug use over the follow-up period was
found at the 01 level when comparing the 2 risk-reduction
interventions to the wellness promotion condition.
CONCLUSIONS
To our knowledge, this is the first RCT to test the efficacy
of a couple-based HIV prevention intervention for drug-using
HIV negative couples. Street outreach recruitment methods that
targeted drug using spots in low income urban neighborhoods,
homeless shelters and soup kitchens, resulted in an unique
sample, the majority of whom were homeless and active crack
cocaine users, engaging in multiple sexual and drug risk
behaviors. The high participation, attendance, and retention
rates achieved in this trial demonstrate the feasibility of
engaging impoverished street-based drug users, who remain at
very high risk of HIV/STIs in a couple-based behavioral
intervention. Furthermore, the observed magnitude and
consistency of findings for the primary behavioral outcome
and across the risk-reduction measures support the 2 major
hypotheses and provide robust evidence of efficacy of the
couple-based HIV prevention intervention.
Statistically significant effect sizes averaged over the
1-year follow-up period were observed for the primary
behavioral outcome for both study hypotheses. When both
risk-reduction intervention arms were combined, there was
a 30% reduction in the incidence rate of unprotected acts of
intercourse with the study partners compared with participants
in the couple wellness promotion arm over the follow-up
period. Although the effect of the intervention was significant
for the overall follow-up period and at IPT and 6 months
follow-up points, it lost significance at 12 months. With
regards to modality effects, participants assigned to couple risk
reduction had a 29% reduction in incidence of unprotected sex
with study partner over the 12-month follow-up period
compared with individual risk-reduction participants. In
contrast to the typical attenuating effects over time observed
for most behavioral interventions in trials, the significance and
effect sizes strengthened over time. At IPT, there was no
significant difference in incidence of unprotected sex acts
between the 2 HIV intervention conditions, however, by
the 12-months follow-up, there was a 41% reduction compared
with participants assigned to the individual condition. The
strengthening of effects over time was also found for the





Reduction (n = 190)
Individual Risk
Reduction (n = 183)
Couple Wellness
Promotion (n = 190)
Length of relationship (yrs)
with study partner
6.4 (6.3) 6.2 (6.0) 6.3 (5.8) 6.6 (7.1)
Number of vaginal sex acts with study
partner in the past 90 days
44.9 (50.3) 42.6 (39.4) 45.3 (51.0) 46.9 (58.9)
Number of unprotected vaginal sex acts with
study partner in the past 90 days
42.0 (49.8) 37.5 (38.8) 43.2 (49.2) 45.2 (59.2)
Number of vaginal sex acts across all
partners in the past 90 days
48.9 (53.0) 47.7 (43.0) 48.9 (52.8) 50.0 (61.9)
Number of unprotected vaginal sex acts across
all partners in the past 90 days
44.3 (51.8) 40.6 (41.7) 44.9 (50.1) 47.5 (61.6)
Number of anal sex acts with study
partner in the past 90 days
3.6 (10.3) 4.0 (9.1) 2.8 (9.8) 4.0 (11.7)
Number of unprotected anal sex acts with study
partner in the past 90 days
3.3 (10.0) 3.4 (8.8) 2.4 (9.3) 3.9 (11.7)
Number of anal sex acts across all
partners in the past 90 days
4.5 (13.4) 5.1 (11.7) 3.9 (14.2) 4.6 (14.1)
Number of unprotected anal sex acts across all
partners in the past 90 days
3.9 (12.2) 4.2 (10.1) 3.2 (12.2) 4.4 (14.0)
Had concurrent partners in the past 90 days 181 (32%) 76 (40%)* 56 (31%)* 49 (26%)*
Number of sexual partners in the past 90 days 2.2 (5.0) 2.6 (3.6) 2.5 (7.7) 1.6 (1.8)
Illicit drug use in the past 30 days 459 (82%) 162 (85%) 143 (78%) 154 (81%)
Binge drinking in the past 30 days 212 (38%) 83 (44%) 68 (37%) 61 (32%)
Injected drugs in the past 30 days 91 (16%) 31 (16%) 33 (18%) 27 (14%)
Shared needle or syringes in the past 30 days 35 (6%) 12 (6%) 13 (7%) 10 (5%)
Shared works, cooker, cotton, or rinse
water in the past 30 days
37 (7%) 12 (6%) 14 (8%) 11 (6%)
Any STI‡ 24 (4%) 6 (3%) 11 (6%) 7 (4%)
*The data for one participant was lost due to computer failure.
†P , 0.05 (x2 test or t test).
‡All the participants had HIV/STI test at the Baseline. The valid sample sizes were (Couple Risk Reduction, Individual Risk Reduction, Couple Wellness Promotion) = (190, 184, 190).
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Number of unprotected vaginal sex acts with study partner in the past 90 days
Couple risk reduction 37.5 (38.8) 25.1 (37.1) 16.1 (21.4) 12.9 (19.2)
Individual risk reduction 43.2 (49.2) 23.0 (29.4) 23.3 (34.6) 18.2 (27.0)
Couple wellness promotion 45.2 (59.2) 37.3 (43.6) 25.8 (32.9) 19.7 (28.1)
Number of unprotected vaginal sex acts across all partners in the past 90 days
Couple risk reduction 40.6 (41.7) 25.4 (37.1) 18.1 (24.2) 15.0 (21.1)
Individual risk reduction 44.9 (50.1) 23.6 (30.1) 26.0 (39.4) 20.0 (28.0)
Couple wellness promotion 47.5 (61.6) 38.1 (44.0) 27.1 (33.2) 22.0 (30.1)
Consistent condom use during vaginal sex with study partner in the past 90 days
Couple risk reduction 17 (9%) 45 (27%) 38 (26%) 51 (36%)
Individual risk reduction 7 (4%) 38 (24%) 30 (23%) 38 (28%)
Couple wellness promotion 7 (4%) 21 (13%) 20 (14%) 44 (30%)
Consistent condom use during vaginal sex across all partners in the past 90 days
Couple risk reduction 17 (9%) 41 (24%) 36 (24%) 40 (28%)
Individual risk reduction 4 (2%) 36 (23%) 22 (17%) 30 (22%)
Couple wellness promotion 7 (4%) 20 (12%) 25 (18%) 36 (24%)
Any unprotected anal sex with study partner in the past 90 days
Couple risk reduction 72 (38%) 30 (18%) 20 (13%) 23 (16%)
Individual risk reduction 53 (29%) 21 (13%) 25 (19%) 18 (13%)
Couple wellness promotion 82 (43%) 42 (26%) 32 (23%) 28 (19%)
Any unprotected anal sex across all partners in the past 90 days
Couple risk reduction 77 (41%) 30 (18%) 21 (14%) 26 (18%)
Individual risk reduction 57 (31%) 22 (14%) 27 (21%) 19 (14%)
Couple wellness promotion 85 (45%) 42 (26%) 35 (25%) 32 (22%)
Had concurrent partners in the past 90 days
Couple risk reduction 76 (40%) 33 (20%) 26 (17%) 34 (24%)
Individual risk reduction 56 (31%) 29 (18%) 23 (18%) 30 (22%)
Couple wellness promotion 49 (26%) 18 (11%) 25 (18%) 29 (20%)
Injected drugs in the past 30 days
Couple risk reduction 31 (16%) 15 (9%) 12 (8%) 9 (6%)
Individual risk reduction 33 (18%) 14 (9%) 7 (5%) 12 (9%)
Couple wellness promotion 27 (14%) 16 (10%) 12 (9%) 17 (12%)
Shared needle or syringes in the past 30 days
Couple risk reduction 12 (6%) 4 (2%) 4 (3%) 1 (1%)
Individual risk reduction 13 (7%) 9 (6%) 4 (3%) 3 (2%)
Couple wellness promotion 10 (5%) 4 (2%) 3 (2%) 5 (3%)
Shared works, cooker, cotton, or rinse water in the past 30 days
Couple risk reduction 12 (6%) 5 (3%) 4 (3%) 3 (2%)
Individual risk reduction 14 (8%) 8 (5%) 4 (3%) 3 (2%)
Couple wellness promotion 11 (6%) 4 (2%) 2 (1%) 6 (4%)
Any STI†
Couple risk reduction 6 (3%) 0 (0%) 4 (3%) 3 (2%)
Individual risk reduction 11 (6%) 4 (3%) 2 (2%) 2 (1%)
Couple wellness promotion 7 (4%) 2 (1%) 3 (2%) 3 (2%)
HIV
Couple risk reduction 0 (0%) — — 1
Individual risk reduction 0 (0%) — — 0
Couple wellness promotion 0 (0%) — — 0
*The data for one participant was lost due to computer failure.
†The sample size was 564 for the baseline and 490 for the IPT.
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couple-based condition with regard to the incidence of
unprotected sex across all main and all other sexual partners.
Furthermore, statistical models with additional covariate
adjustments of sociodemographic characteristics also yielded
the same significant findings.
These findings suggest that when couples receive the
intervention together, they are more likely to improve and
sustain positive protective behaviors over time compared with
when 1 partner receives the intervention alone. Further
research is needed to explain what mediators or mechanisms
explain the robust maintenance of intervention effects for the
couple modality compared with the individual modality. The
strong maintenance of intervention effects over time suggests
superior cost-effectiveness of delivering this relationship-
based intervention using a couple-based modality over the
individual modality.
Although the intervention effects on injection drug risk
behavior was not significant at the 005 level, promising effects
were found at the 01 level, underscoring the potential utility
of employing a couple-based approach in reducing drug risks.
The study was not powered to examine the effects of the
intervention on incidence of HIV and STIs. Among the 428
12-month follow-up participants, 1 participant assigned to the
couple risk reduction seroconverted, which translates to 234
positives per 100,000 population. (This rate was much greater
than the estimated new HIV incidence rate of 232 per 100,000
population for the US general population in 2006.23 Incidence of
STIs was low at 23 (4%) over the 12-month period, and these rates
were similar across conditions. The lack of significant biologically
STI outcome is a limitation of this study. How individuals who
engage in HIV risks remain HIV seronegative is a conundrum
that has not been adequately studied. It requires future studies
with larger sample sizes to be suitably powered for a sufficient
number of HIV and STI transmissions to elucidate this
mechanism of great public health and biomedical importance.
The study has a number of strengths. It employed an
RCT, with a dose and modality equivalent control group and
an active comparison relationship-based intervention that
covered the same content as the experimental condition but
was delivered to 1 partner. The street outreach recruitment
methods resulted in a unique sample of HIV-negative drug
users, most of whom were homeless, engaging in multiple
risky behaviors, and not in drug treatment despite reporting
heavy use of crack cocaine and other drugs. The large number
of homeless people and use of multiple settings may limit its
generalizeability to any one setting. However, the use of street
outreach recruitment methods may be generalizable to
a number of settings that serve similar vulnerable populations
who remain at high risk of HIV, including syringe exchange
programs, street outreach programs, homeless shelters, and
criminal justice settings. Selection bias arising from refusals to
participate and attrition may have influenced study results.
Nonetheless, the relatively high participation, retention, and
attendance rates achieved in this study despite the fact that the
majority of participants were homeless demonstrate the
feasibility and importance of including participants without
TABLE 4. Longitudinal Multilevel Analysis of HIV Sexual Risk Behaviors in the Past 90 Days: Effect Estimates and 95% CIs
Entire Follow-up IPT 6 Months 12 Months
Number of unprotected vaginal sex acts with study partner (IRR)
Intervention (risk reduction vs. wellness promotion) 0.70 (0.53 to 0.92)* 0.58 (0.38 to 0.88)* 0.70 (0.54 to 0.92)† 0.85 (0.55 to 1.32)
Modality (couple risk vs. individual risk) 0.71 (0.51 to 0.97)† 0.84 (0.52 to 1.35) 0.70 (0.51 to 0.96)† 0.59 (0.35 to 0.99)†
Number of unprotected vaginal sex acts across all partners (IRR)
Intervention (risk reduction vs. wellness promotion) 0.69 (0.54 to 0.88)* 0.59 (0.41 to 0.86)* 0.69 (0.54 to 0.88)* 0.81 (0.55 to 1.19)
Modality (couple risk vs. individual risk) 0.74 (0.56 to 0.99)† 0.89 (0.57 to 1.37) 0.74 (0.56 to 0.98)† 0.62 (0.39 to 0.98)†
Consistent condom use during vaginal sex with study partner (OR)
Intervention (risk reduction vs. wellness promotion) 2.07 (1.25 to 3.45)* 4.09 (1.76 to 9.49)* 2.16 (1.29 to 3.61)* 1.14 (0.54 to 2.40)
Modality (couple risk vs. individual risk) 1.18 (0.68 to 2.03) 0.94 (0.40 to 2.17) 1.18 (0.68 to 2.02) 1.48 (0.63 to 3.48)
Consistent condom use during vaginal sex across all partners (OR)
Intervention (risk reduction vs. wellness promotion) 1.56 (0.98 to 2.47) 2.85 (1.34 to 6.06)* 1.61 (1.01 to 2.55)† 0.91 (0.45 to 1.81)
Modality (couple risk vs. individual risk) 1.19 (0.71 to 1.98) 0.96 (0.44 to 2.07) 1.20 (0.72 to 1.99) 1.50 (0.66 to 3.38)
Any unprotected anal sex with study partner (OR)
Intervention (risk reduction vs. wellness promotion) 0.65†(0.42 to 1.02)‡ 0.52 (0.27 to 1.03)‡ 0.66 (0.42 to 1.03)‡ 0.83 (0.40 to 1.72)
Modality (couple risk vs. individual risk) 0.90 (0.52 to 1.56) 0.85 (0.37 to 1.96) 0.90 (0.52 to 1.56) 0.95 (0.39 to 2.30)
Any unprotected anal sex across all partners (OR)
Intervention (risk reduction vs. wellness promotion) 0.61 (0.39 to 0.94)† 0.53 (0.27 to 1.04)‡ 0.61 (0.40 to 0.95)† 0.70 (0.35 to 1.42)
Modality (couple risk vs. individual risk) 0.83 (0.48 to 1.42) 0.73 (0.32 to 1.66) 0.83 (0.49 to 1.43) 0.95 (0.40 to 2.25)
Had concurrent partners (OR)
Intervention (risk reduction vs. wellness promotion) 1.06 (0.71 to 1.58) 1.36 (0.71 to 2.61) 1.08 (0.72 to 1.61) 0.85 (0.46 to 1.56)
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permanent addresses, who have been typically excluded in
most trials with drug users.
In sum, the findings draw attention to an effective
intervention strategy that can be scaled-up for drug-involved
couples in harm-reduction programs, drug treatment, and
criminal justice systems. HIV prevention with at-risk
heterosexual drug users in low-income urban neighborhoods
with concentrated epidemics remains a priority and essential to
achieving the 25% reduction of new infections and reducing
HIV/AIDS-related racial/ethnic disparities 2015 goals of our
recent national HIV strategic plan. A couple-based approach to
primary prevention of HIV that addresses both drug and sexual
risks and targets low-income urban active drug users may help
curb the HIV epidemic in the United States and may have
dissemination potential to address the global HIV epidemic.
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